Published in Cancer Res on January 01, 2004
Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med (2004) 2.86
Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med (2008) 1.93
Killing a cancer: what are the alternatives? Nat Rev Cancer (2012) 1.30
Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res (2011) 1.27
Carbon black and titanium dioxide nanoparticles elicit distinct apoptotic pathways in bronchial epithelial cells. Part Fibre Toxicol (2010) 1.22
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer (2009) 1.11
Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem (2012) 1.10
Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J Cell Mol Med (2008) 1.09
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res (2005) 1.04
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics (2011) 0.96
Pterostilbene simultaneously induced G0/G1-phase arrest and MAPK-mediated mitochondrial-derived apoptosis in human acute myeloid leukemia cell lines. PLoS One (2014) 0.95
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol (2007) 0.94
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev (2013) 0.90
In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-assisted label-free protein quantitation and microarray gene expression approach. Mol Cell Proteomics (2011) 0.90
Lysosomal destabilization contributes to apoptosis of germinal center B-lymphocytes. J Histochem Cytochem (2006) 0.90
Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS One (2013) 0.90
Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop. J Cell Mol Med (2008) 0.86
Proteomic analysis of enriched lysosomes at early phase of camptothecin-induced apoptosis in human U-937 cells. J Proteomics (2009) 0.86
Cytolethal distending toxin induces caspase-dependent and -independent cell death in MOLT-4 cells. Infect Immun (2008) 0.85
Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget (2017) 0.84
Proteases inhibition assessment on PC12 and NGF treated cells after oxygen and glucose deprivation reveals a distinct role for aspartyl proteases. PLoS One (2011) 0.84
Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy. Cancer Invest (2009) 0.82
Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression. Mol Cancer (2011) 0.82
Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells. PLoS One (2012) 0.81
Mouse embryonic stem cells undergo charontosis, a novel programmed cell death pathway dependent upon cathepsins, p53, and EndoG, in response to etoposide treatment. Stem Cell Res (2013) 0.81
Changes in liver proteome expression of Senegalese sole (Solea senegalensis) in response to repeated handling stress. Mar Biotechnol (NY) (2012) 0.81
Cathepsin B is activated as an executive protease in fetal rat alveolar type II cells exposed to hyperoxia. Exp Mol Med (2011) 0.80
A Microbial Feed Additive Abates Intestinal Inflammation in Atlantic Salmon. Front Immunol (2015) 0.78
Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res (2015) 0.78
Gene expression profiling in the lung tissue of cynomolgus monkeys in response to repeated exposure to welding fumes. Arch Toxicol (2010) 0.78
Interleukin-10 down-regulates cathepsin B expression in fetal rat alveolar type II cells exposed to hyperoxia. Yonsei Med J (2013) 0.77
Anti-Metastatic and Anti-Angiogenic Activities of Core-Shell SiO2@LDH Loaded with Etoposide in Non-Small Cell Lung Cancer. Adv Sci (Weinh) (2016) 0.76
Inhibition of cancer cell proliferation and apoptosis-inducing activity of fungal taxol and its precursor baccatin III purified from endophytic Fusarium solani. Cancer Cell Int (2013) 0.75
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol (2013) 0.75
Protein kinase C-δ isoform mediates lysosome labilization in DNA damage-induced apoptosis. Int J Oncol (2010) 0.75
Geranylated 4-Phenylcoumarins Exhibit Anticancer Effects against Human Prostate Cancer Cells through Caspase-Independent Mechanism. PLoS One (2016) 0.75
Non-Canonical Cell Death Induced by p53. Int J Mol Sci (2016) 0.75
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr Relat Cancer (2017) 0.75
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood (2011) 2.12
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer (2006) 1.67
Sexual uses of alcohol and drugs and the associated health risks: a cross sectional study of young people in nine European cities. BMC Public Health (2008) 1.63
Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol (2007) 1.60
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood (2010) 1.56
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol (2007) 1.48
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.41
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34
TGF-β as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol (2012) 1.33
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer (2006) 1.33
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell (2006) 1.33
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30
Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol (2005) 1.30
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther (2006) 1.28
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res (2012) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer (2007) 1.21
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.21
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract (2011) 1.16
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 1.16
Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol (2010) 1.15
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol (2004) 1.13
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.12
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res (2010) 1.12
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther (2007) 1.11
Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl (2007) 1.10